SK284572B6 - Vakcíny obsahujúce adjuvans LTB a použitie podjednotky B tepelne-labilného enterotoxínu - Google Patents
Vakcíny obsahujúce adjuvans LTB a použitie podjednotky B tepelne-labilného enterotoxínu Download PDFInfo
- Publication number
- SK284572B6 SK284572B6 SK776-2000A SK7762000A SK284572B6 SK 284572 B6 SK284572 B6 SK 284572B6 SK 7762000 A SK7762000 A SK 7762000A SK 284572 B6 SK284572 B6 SK 284572B6
- Authority
- SK
- Slovakia
- Prior art keywords
- subunit
- ltb
- vaccine
- immunogen
- mucosal
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 37
- 239000002671 adjuvant Substances 0.000 title claims abstract description 21
- 101710146739 Enterotoxin Proteins 0.000 title claims abstract description 7
- 239000000147 enterotoxin Substances 0.000 title claims abstract description 7
- 231100000655 enterotoxin Toxicity 0.000 title claims abstract description 7
- 239000000427 antigen Substances 0.000 claims abstract description 38
- 108091007433 antigens Proteins 0.000 claims abstract description 38
- 102000036639 antigens Human genes 0.000 claims abstract description 38
- 230000002163 immunogen Effects 0.000 claims abstract description 21
- 230000009885 systemic effect Effects 0.000 claims abstract description 11
- 229930186900 holotoxin Natural products 0.000 claims abstract description 10
- 230000001939 inductive effect Effects 0.000 claims abstract description 8
- 241000588724 Escherichia coli Species 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 7
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract 2
- 206010022000 influenza Diseases 0.000 claims description 21
- 230000004044 response Effects 0.000 claims description 14
- 230000002588 toxic effect Effects 0.000 claims description 11
- 231100000331 toxic Toxicity 0.000 claims description 10
- 210000004877 mucosa Anatomy 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000003053 immunization Effects 0.000 claims description 5
- 238000002649 immunization Methods 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 206010065764 Mucosal infection Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 230000016379 mucosal immune response Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000005875 antibody response Effects 0.000 abstract description 20
- 241000894006 Bacteria Species 0.000 abstract description 7
- 244000052769 pathogen Species 0.000 abstract description 6
- 230000001717 pathogenic effect Effects 0.000 abstract description 5
- 241000233866 Fungi Species 0.000 abstract description 2
- 241000537222 Betabaculovirus Species 0.000 abstract 1
- 101710154606 Hemagglutinin Proteins 0.000 description 26
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 26
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 26
- 101710176177 Protein A56 Proteins 0.000 description 26
- 239000000185 hemagglutinin Substances 0.000 description 26
- 101000764294 Homo sapiens Lymphotoxin-beta Proteins 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 23
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 22
- 241000700605 Viruses Species 0.000 description 17
- 238000002255 vaccination Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 102000009016 Cholera Toxin Human genes 0.000 description 8
- 108010049048 Cholera Toxin Proteins 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 229940031626 subunit vaccine Drugs 0.000 description 8
- 206010002091 Anaesthesia Diseases 0.000 description 7
- 230000037005 anaesthesia Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000001571 immunoadjuvant effect Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007123 defense Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000568 immunological adjuvant Substances 0.000 description 3
- 229960003971 influenza vaccine Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 102000055414 human LTB Human genes 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007108 local immune response Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 229940126577 synthetic vaccine Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010073753 Fear of injection Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 101150018411 LTB gene Proteins 0.000 description 1
- 241001374849 Liparis atlanticus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012628 flowing agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97203671A EP0919243A1 (en) | 1997-11-25 | 1997-11-25 | Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant |
| PCT/EP1998/007553 WO1999026654A1 (en) | 1997-11-25 | 1998-11-24 | Vaccines with an ltb adjuvant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK7762000A3 SK7762000A3 (en) | 2000-11-07 |
| SK284572B6 true SK284572B6 (sk) | 2005-06-02 |
Family
ID=8228966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK776-2000A SK284572B6 (sk) | 1997-11-25 | 1998-11-24 | Vakcíny obsahujúce adjuvans LTB a použitie podjednotky B tepelne-labilného enterotoxínu |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6793928B1 (enExample) |
| EP (2) | EP0919243A1 (enExample) |
| JP (1) | JP4235359B2 (enExample) |
| KR (1) | KR100575019B1 (enExample) |
| CN (1) | CN1227032C (enExample) |
| AT (1) | ATE238809T1 (enExample) |
| AU (1) | AU747061C (enExample) |
| BR (1) | BR9815413A (enExample) |
| CA (1) | CA2311492C (enExample) |
| CZ (1) | CZ299770B6 (enExample) |
| DE (1) | DE69814177T2 (enExample) |
| DK (1) | DK1071456T3 (enExample) |
| ES (1) | ES2198089T3 (enExample) |
| HU (1) | HU226214B1 (enExample) |
| IL (2) | IL135905A0 (enExample) |
| NO (1) | NO324690B1 (enExample) |
| NZ (1) | NZ504396A (enExample) |
| PL (1) | PL190925B1 (enExample) |
| PT (1) | PT1071456E (enExample) |
| RU (1) | RU2211050C2 (enExample) |
| SK (1) | SK284572B6 (enExample) |
| TR (1) | TR200001485T2 (enExample) |
| UA (1) | UA72199C2 (enExample) |
| WO (1) | WO1999026654A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| KR20010043441A (ko) | 1998-05-08 | 2001-05-25 | 더 유니버시티 오브 브리스톨 | 백신용 면역조절제 |
| AU2003261492B2 (en) * | 1998-05-08 | 2006-09-07 | Trident Pharmaceuticals, Inc. | Vaccine |
| EP1075274A2 (en) * | 1998-05-08 | 2001-02-14 | University Of Bristol | Immunomodulators for vaccines |
| EP1221970B1 (en) * | 1999-10-18 | 2014-02-19 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for stimulating an immune response against infectious agents |
| RU2223783C1 (ru) * | 2002-07-05 | 2004-02-20 | Российская медицинская академия последипломного образования | Способ профилактики гриппа и острых респираторных заболеваний у часто болеющих детей |
| IL158140A0 (en) * | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
| EP1708744A4 (en) * | 2003-12-09 | 2009-07-15 | Intercell Usa Inc | GM1 Binding Dereficent Exotoxins for Use as Immunoinguarantees |
| EP1930025B1 (en) | 2005-08-05 | 2013-05-01 | The University of Tokushima | ANTIGEN-AND-DRUG VEHICLE WHICH ENABLES THE CHANGEOVER FROM THE SELECTIVE PRODUCTION OF IgA ANTIBODY TO THE PRODUCTION OF BOTH OF IgA AND IgG ANTIBODIES, AND TRANSNASAL/TRANSMUCOSAL VACCINE USING THE VEHICLE |
| TWI397419B (zh) * | 2006-03-22 | 2013-06-01 | Abbott Biologicals Bv | 病毒顆粒的鼻內或吸入給藥 |
| US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| CN101522706B (zh) | 2006-10-12 | 2013-09-04 | P.安杰莱蒂分子生物学研究所 | 端粒酶逆转录酶融合蛋白、编码它的核苷酸以及其用途 |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| CA2697373C (en) | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| AU2008343745B2 (en) | 2007-10-01 | 2012-05-10 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
| CA3207612A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| CN104379170B (zh) * | 2012-06-20 | 2017-05-03 | 国立大学法人东京大学 | 粘膜免疫刺激剂及hpv感染症治疗用经口药物组合物 |
| CN106170551B (zh) | 2013-12-16 | 2020-01-07 | 财团法人农业科技研究院 | 生产不耐热肠毒素b亚单位的质粒、方法及其套组 |
| EP3294448A4 (en) | 2015-05-14 | 2018-12-12 | Longhorn Vaccines and Diagnostics, LLC | Rapid methods for the extraction of nucleic acids from biological samples |
| CN111344397A (zh) * | 2017-11-01 | 2020-06-26 | 默沙东公司 | 巨细胞病毒的稳定制剂 |
| AU2019207600B2 (en) | 2018-01-09 | 2025-01-09 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
| EP3768302B1 (en) | 2018-03-20 | 2025-05-07 | Theriva Biologics, Inc. | Intestinal alkaline phosphatase formulations |
| EP4275761A3 (en) | 2018-03-20 | 2024-02-28 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
| WO2020227263A1 (en) | 2019-05-06 | 2020-11-12 | Synthetic Biologics, Inc. | Alkaline phosphate-based oncology treatments |
| EP3975999A4 (en) | 2019-06-03 | 2023-07-19 | Theriva Biologics, Inc. | ALKALINE PHOSPHATASE FORMULATIONS AND THEIR USES |
| US12485166B2 (en) | 2020-02-06 | 2025-12-02 | Longhorn Vaccines And Diagnostics, Llc | Vaccines for the treatment and prevention of zoonotic infections |
| CN113616783B (zh) * | 2020-05-08 | 2025-08-08 | 昱厚生技股份有限公司 | 使用免疫调节剂和包含所述免疫调节剂的疫苗组合物预防或治疗冠状病毒感染的方法 |
| KR20230091978A (ko) | 2020-10-20 | 2023-06-23 | 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 | 면역원성 항원 |
| TWI896302B (zh) * | 2024-08-22 | 2025-09-01 | 國立清華大學 | 重組蛋白及其製備方法、包含重組蛋白的疫苗蛋白質佐劑及重組蛋白用於預防呼吸道疾病的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH589453A5 (enExample) | 1974-01-14 | 1977-07-15 | Sandoz Ag | |
| JP2849632B2 (ja) * | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
| AU4754490A (en) * | 1988-12-07 | 1990-06-26 | University Of Leicester | Heat-labile toxin b subunit fusion proteins |
| US5241053A (en) * | 1990-09-05 | 1993-08-31 | Takeda Chemical Industries, Ltd. | Fused proteins comprising glycoprotein gD of HSV-1 and LTB |
| GB9513733D0 (en) * | 1995-07-05 | 1995-09-06 | Univ Bristol | Therapeutic agents |
-
1997
- 1997-11-25 EP EP97203671A patent/EP0919243A1/en not_active Withdrawn
-
1998
- 1998-11-24 RU RU2000116260/14A patent/RU2211050C2/ru not_active IP Right Cessation
- 1998-11-24 US US09/555,139 patent/US6793928B1/en not_active Expired - Fee Related
- 1998-11-24 BR BR9815413-3A patent/BR9815413A/pt not_active IP Right Cessation
- 1998-11-24 CN CNB988115492A patent/CN1227032C/zh not_active Expired - Fee Related
- 1998-11-24 AU AU18750/99A patent/AU747061C/en not_active Ceased
- 1998-11-24 SK SK776-2000A patent/SK284572B6/sk not_active IP Right Cessation
- 1998-11-24 CZ CZ20001895A patent/CZ299770B6/cs not_active IP Right Cessation
- 1998-11-24 WO PCT/EP1998/007553 patent/WO1999026654A1/en not_active Ceased
- 1998-11-24 NZ NZ504396A patent/NZ504396A/en not_active IP Right Cessation
- 1998-11-24 IL IL13590598A patent/IL135905A0/xx active IP Right Grant
- 1998-11-24 EP EP98963503A patent/EP1071456B1/en not_active Expired - Lifetime
- 1998-11-24 ES ES98963503T patent/ES2198089T3/es not_active Expired - Lifetime
- 1998-11-24 JP JP2000521855A patent/JP4235359B2/ja not_active Expired - Fee Related
- 1998-11-24 CA CA2311492A patent/CA2311492C/en not_active Expired - Fee Related
- 1998-11-24 UA UA2000063620A patent/UA72199C2/uk unknown
- 1998-11-24 TR TR2000/01485T patent/TR200001485T2/xx unknown
- 1998-11-24 PT PT98963503T patent/PT1071456E/pt unknown
- 1998-11-24 PL PL340635A patent/PL190925B1/pl unknown
- 1998-11-24 DE DE69814177T patent/DE69814177T2/de not_active Expired - Lifetime
- 1998-11-24 HU HU0100058A patent/HU226214B1/hu not_active IP Right Cessation
- 1998-11-24 KR KR1020007005665A patent/KR100575019B1/ko not_active Expired - Fee Related
- 1998-11-24 AT AT98963503T patent/ATE238809T1/de active
- 1998-11-24 DK DK98963503T patent/DK1071456T3/da active
-
2000
- 2000-05-01 IL IL135905A patent/IL135905A/en not_active IP Right Cessation
- 2000-05-22 NO NO20002613A patent/NO324690B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1071456B1 (en) | Vaccines with an ltb adjuvant | |
| US8182821B2 (en) | Flu vaccine admixture of mannan and flu antigen | |
| NO323555B1 (no) | Influensavaksine, farmasoytisk utstyr og anvendelse av kitosan. | |
| WO2000018434A1 (en) | Mutant cholera holotoxin as an adjuvant | |
| de Haan et al. | Mutational analysis of the role of ADP‐ribosylation activity and GM1‐binding activity in the adjuvant properties of the Escherichia coli heat‐labile enterotoxin towards intranasally administered keyhole limpet hemocyanin | |
| Larsen et al. | Effects of DNA dose, route of vaccination, and coadministration of porcine interleukin-6 DNA on results of DNA vaccination against influenza virus infection in pigs | |
| EP0725653A1 (en) | Vaccine compositions | |
| Glück | Intranasal immunization against influenza | |
| JP5913406B2 (ja) | 変異型大腸菌易熱性エンテロトキシン | |
| WO2008037033A1 (en) | Flu vaccine admixture of mannan and flu antigen | |
| Morein et al. | New ISCOMs meet unsettled vaccine demands | |
| EP1221970B1 (en) | Compositions and methods for stimulating an immune response against infectious agents | |
| PT721782E (pt) | Vacina contra a gripe contendo toxina da tosse convulsa | |
| HK1031102B (en) | Vaccines with an ltb adjuvant | |
| MXPA00005127A (en) | Vaccines with an ltb adjuvant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC4A | Change of owner's name |
Owner name: ABBOTT BIOLOGICALS B.V., CP WEESP, NL Effective date: 20120830 |
|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20131124 |